

**1. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.**

Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, **Smith S**, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.

J Vet Intern Med. 2018 Jan;32(1):72-85.

**2. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.**

Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, **Smith S**, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.

J Vet Intern Med. 2016 Nov;30(6):1765-1779.

**3. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.**

Häggström J, Boswood A, O'Grady M, Jöns O, **Smith S**, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kwart C, French A, Rønn-Landbo M, Wess G, Eggertsdóttir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.

J Vet Intern Med. 2013 Nov-Dec;27(6):1441-51.

**4. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study).**

Summerfield NJ, Boswood A, O'Grady MR, Gordon SG, Dukes-McEwan J, Oyama MA, **Smith S**, Patteson M, French AT, Culshaw GJ, Braz-Ruivo L, Estrada A, O'Sullivan ML, Loureiro J, Willis R, Watson P.

J Vet Intern Med. 2012 Nov-Dec;26(6):1337-49.

**5. Clinical signs and left atrial size in cats with cardiovascular disease in general practice.**

**Smith S**, Dukes-McEwan J.

J Small Anim Pract. 2012 Jan;53(1):27-33.

**6. Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.**

Boswood A, **Smith S**, Patteson M.

Vet Rec. 2011 Feb 26;168(8):222.

**7. A retrospective study of 153 cases of undiagnosed collapse, syncope or exercise intolerance: the outcomes.**

Barnett L, Martin MW, Todd J, **Smith S**, Cobb M.

J Small Anim Pract. 2011 Jan;52(1):26-31.

**8. Treatment of congestive heart failure in dogs.**

Boswood A, Dukes-McEwan J, French A, Little C, Patteson M, **Swift S**, Smith S, Willis R.  
Vet Rec. 2008 Oct 25;163(17):520.

**9. Canine dynamic left ventricular outflow tract obstruction: assessment of myocardial function and clinical outcome.**

Loureiro J, Smith S, Fonfara S, **Swift S**, James R, Dukes-McEwan J.  
J Small Anim Pract. 2008 Nov;49(11):578-86.

**10. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.**

Hägström J, Boswood A, O'Grady M, Jöns O, Smith S, **Swift S**, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvarn C, French A, Rønn-Landbo M, Wess G, Eggertsdóttir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFrancia R.  
J Vet Intern Med. 2008 Sep-Oct;22(5):1124-35.

**11. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease".**

Corcoran B, Culshaw G, Dukes-McEwan J, French A, **Smith S**, Swift S.  
J Vet Intern Med. 2008 Mar-Apr;22(2):243; author reply 245.

**12. Preclinical dilated cardiomyopathy in the dobermann.**

Summerfield N, Dukes-McEwan J, Swift S, Patteson M, Wotton P, Martin M, Johnson M, Boswood A, Fuentes VL, French A, Culshaw G, Little C, Smith P, **Smith S**, Willis R.  
Vet Rec. 2006 May 27;158(21):742-3.

**13. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease.**

Smith PJ, French AT, Van Israël N, **Smith SG**, Swift ST, Lee AJ, Corcoran BM, Dukes-McEwan J.  
J Small Anim Pract. 2005 Mar;46(3):121-30.

**14. Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.**

Boswood A, McEwan JD, French A, Little C, Swift S, **Smith S**, Patteson M.  
Vet Rec. 2003 Oct 4;153(14):439-40.